Optimi Health Corp (CNSX: OPTI) (OTCMKTS: OPTHF) (FRA: 8BN) announced on Apr. 20 that it will begin manufacturing ibogaine.
The Canadian company launched this initiative after President Donald Trump signed an executive order on Apr. 18 that directs federal agencies to speed up research, reviews and patient access to certain psychedelic medicines, including ibogaine.
Optimi plans to use its existing licensed manufacturing platform to produce and supply the compound, which researchers study for opioid use disorder, PTSD and traumatic brain injury. The psychedelic drug producer states it stands ready to meet emerging demand created by the order, which also confirms new U.S. clinical trial clearances and funding support.
Optimi Health operates as a commercial pharmaceutical manufacturer based in Vancouver, British Columbia. It focuses on producing finished drug products from psychedelics and ships them directly to authorized clinics, pharmacies, and research programs in countries where medical use is legal.
The company already supplies MDMA for PTSD treatment and psilocybin for depression under regulated programs. For instance, it exports these medicines to clinics in Australia that treat patients who do not respond to conventional therapies.
With its Health Canada-licensed facility, Optimi holds a strong position in the legal psychedelics sector, where the emphasis stays on safe, regulated supply chains that support clinical care and research rather than unregulated markets.
Read more: Israeli scientists get tobacco to produce an array of psychedelic compounds
Other psychedelic stocks surge on Trump’s order
Strong investor reaction to the executive order drove sharp gains in psychedelic stocks on Monday. COMPASS Pathways PLC (NASDAQ: CMPS) (FRA: 5Y6), a company developing psilocybin treatments for hard-to-treat depression, saw its shares jump more than 42 per cent.
AtaiBeckley Inc (NASDAQ: ATAI) (FRA: B72), which advances several psychedelic therapies including a mebufotenin nasal spray for depression, rose about 22 per cent.
Additionally, Irish psychedelic therapeutic specialist GH Research PLC (NASDAQ: GHRS) (FRA: 1KA) saw gains in excess of 17 per cent during Monday’s session on the Nasdaq.
This market surge reflects broad confidence that faster federal pathways could open new opportunities. The enthusiasm contributed directly to Optimi’s swift decision to add ibogaine production as the order signalled immediate business potential for regulated suppliers.
have a feeling psychedelic stocks will just go apeshit. imho the $PSIL could 10x long-term & trials will be raging successes. the shit works, i know from experience. i'd also like to find a way to short SSRIs. psilocybin & mdma could make them irrelevant. great for humanity imo
— Quoth the Raven (@QTRResearch) April 20, 2026
Trump’s decision will reshape North American psychedelics sector
The American leader’s executive order sets the stage for major growth across the North American psychedelic drugs industry.
It instructs the Food and Drug Administration to issue priority review vouchers that can shorten approval timelines for promising therapies. The order also creates a pathway under the Right to Try Act so eligible patients can access investigational psychedelics, including ibogaine, before full approval.
In addition, it commits at least US$50 million in federal funding to match state investments in research, building on Texas’s existing US$50 million program for ibogaine studies.
These steps will accelerate clinical trials, lower barriers for developers and expand access for veterans and others facing treatment-resistant mental health conditions. Analysts expect increased investment, more state-federal partnerships and steady progress toward regulated medical options throughout the United States and Canada.
Read more: Deutsche Bank initiates bullish coverage of psychedelics company AtaiBeckley
Follow Rowan Dunne on LinkedIn
rowan@mugglehead.com
